- Home
- IFRX vs SRTS Comparison
IFRX vs SRTS Comparison
Compare IFRX & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- SRTS
- Stock Information
- Founded
- IFRX 2007
- SRTS 2010
- Country
- IFRX Germany
- SRTS United States
- Employees
- IFRX N/A
- SRTS 54
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- IFRX Health Care
- SRTS Health Care
- Exchange
- IFRX Nasdaq
- SRTS Nasdaq
- Market Cap
- IFRX 53.5M
- SRTS 51.8M
- IPO Year
- IFRX 2017
- SRTS 2016
- Fundamental
- Price
- IFRX $1.14
- SRTS $3.15
- Analyst Decision
- IFRX Strong Buy
- SRTS Strong Buy
- Analyst Count
- IFRX 5
- SRTS 3
- Target Price
- IFRX $7.40
- SRTS $8.00
- AVG Volume (30 Days)
- IFRX 1.0M
- SRTS 87.1K
- Earning Date
- IFRX 11-07-2025
- SRTS 11-13-2025
- Dividend Yield
- IFRX N/A
- SRTS N/A
- EPS Growth
- IFRX N/A
- SRTS N/A
- EPS
- IFRX N/A
- SRTS N/A
- Revenue
- IFRX $191,224.00
- SRTS $37,564,000.00
- Revenue This Year
- IFRX N/A
- SRTS N/A
- Revenue Next Year
- IFRX $1,216.24
- SRTS $46.14
- P/E Ratio
- IFRX N/A
- SRTS N/A
- Revenue Growth
- IFRX 54.36
- SRTS 3.29
- 52 Week Low
- IFRX $0.71
- SRTS $3.03
- 52 Week High
- IFRX $2.82
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- IFRX 45.40
- SRTS 35.90
- Support Level
- IFRX $1.45
- SRTS $3.16
- Resistance Level
- IFRX $1.77
- SRTS $3.29
- Average True Range (ATR)
- IFRX 0.21
- SRTS 0.12
- MACD
- IFRX -0.04
- SRTS 0.05
- Stochastic Oscillator
- IFRX 24.94
- SRTS 10.81
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.